Site-directed mutagenesis was used to investigate the molecular interactions involved in sarpogrelate binding
The 5-HT 2 serotonin receptors (5-HT 2 R) that belong to the super family of G-protein coupled receptors are of significant clinical interest because of their potential involvement in cardiovascular function and in certain mental disorders. The 5-HT 2C receptor is a subtype of 5-HT 2 R family and share a high degree of amino acid sequence homology (68-79% in the transmembrane segments), similar pharmacological profiles and signal transduction systems with other 5-HT 2 receptor subtypes (5-HT 2A and 5-HT 2B receptors).
1) Activation of 5-HT 2C receptor results in Phospholipase C-mediated Phosphatidylinositol (PI) lipid hydrolysis, 2, 3) which liberates the second messengers diacylglycerol and inositol triphosphates. It is of now-a-days interest to give more emphasis for identification of more selective ligands to fully elucidate the functional role of different subtypes. Molecular modeling and site-directed mutagenesis studies are helpful to determine the activity of currently existing agents and the development of completely novel therapeutic agents. 4) Sarpogrelate, a 5-HT 2 antagonist, was introduced as a therapeutic agent for the treatment of ischemic diseases associated with thrombosis.
5) It inhibits thrombus formation, 6, 7) lowers platelet aggregation, 8, 9) inhibits both serotonin-induced coronary artery spasm, 10) and contraction 11) in porcine model as well as vascular smooth muscle cell proliferation. 12) Presently these pathophysiological effects are claimed to be mediated by 5-HT 2A receptors. Based on radio-ligand binding and molecular modeling studies, sarpogrelate showed a moderate selectivity for 5-HT 2A receptor vs. 5-HT 2C receptor. 13) To confirm the molecular modeling data of sarpogrelate to 5-HT 2C receptors, which predicted that sarpogrelate makes strong electrostatic interactions towards Asp3.32 in transmembrane helix 3 and Ser7.46 in transmembrane helix 7 of 5-HT 2C receptors, we constructed and characterized the mutations of these amino acid residues by site-directed mutagenesis. Our findings are consistent with the molecular modeling data and suggest that these amino acid residues are important for sarpogrelate binding which have been evident from the markedly decrease in affinity of sarpogrelate for the mutant receptors.
MATERIALS AND METHODS

Construction of Expression Plasmids for Human Serotonin 5-HT 2C Receptor Variants
A cDNA clone encoding human 5-HT 2C receptor (Clontech Laboratories, CA, U.S.A.) was digested with BamHI and XbaI and ligated into BamHI and XbaI-digested pUC18 (Takara Bio Inc., Japan). The insert was subcloned into the BamHI and XbaI sites of pcDNA 3.1(+) (Invitrogen, CA, U.S.A.) for expression. Based upon pcDNA3.1(+)/5-HT 2C receptor, we constructed its three mutants to express three different 5-HT 2C receptor variants: pcDNA3.1(+)/5-HT 2C Asp3.32Ala for 5-HT 2C receptor containing an Asp3.32Ala substitution, pcDNA3.1(+)/5-HT 2C Ser7.46Ala for 5-HT 2C receptor containing a Ser7.46Ala substitution, and pcDNA3.1(+)/5-HT 2C Asp3.32Ala/Ser7.46Ala for 5-HT 2C receptor containing Asp3.32Ala and Ser7.46Ala substitutions. The first two mutants were generated by site-directed mutagenesis by overlap extension using PCR [14] [15] [16] and the last one was constructed from these mutants by the conventional recombinant DNA techniques. PCR was performed under the standard conditions using Pyrobest DNA polymerase (Takara Shuzo, Japan) that has a proof-reading activity. Each modified DNA fragment from PCR was double-digested with Bsu36I and PpuMI, and cloned between Bsu36I and PpuMI sites of pcDNA3.1(+)/5-HT 2C receptor. We confirmed that the insert sequences are changed correctly by DNA sequencing.
Cell Culture and Transfection COS-7 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. COS-7 cells were transiently transfected in 10-cm dishes at about 80% confluence with Polyfect Transfection Reagent using the manufacturer's protocol (Qiagen, U.S.A. Ϫ3 M for mutants) and antagonists in assay medium were added to each well and incubated for 1 h at 37°C by floating the plates in a temperature-controlled water bath. Assay medium was removed and the reaction was stopped by adding 1 ml of 10 mM formic acid (previously stored at 4°C) to each well. The plates were stored at 4°C for 2 h and cells were neutralized by adding 1 ml 500 mM KOH and 9 mM sodium tetraborate per well. The contents of each well were extracted and centrifuged for 5 min at 1400ϫg and the upper layer loaded onto a 1-ml AG1-X8 resin (100-200 mesh, Assist Co., Japan) column. Columns were washed 2 times with 5 ml 60 mM sodium formate and 5 mM borax. Total IPs were eluted with 5 ml 1 M ammonium formate and 0.1 M formic acid. Radioactivity was measured by liquid scintillation spectrophotometry.
Ligand Binding Assays Transiently transfected COS-7 cells were grown in 10-cm plates. The plates were washed in phosphate-buffered saline (PBS), and cells were harvested by scraping with a rubber policeman. Cells were centrifuged at 14000ϫg for 2 min. After removing the supernatant, cell pellets were stored at Ϫ80°C until use. For the preparation of membranes, cell pellets were thawed and homogenized in 1 ml of 50 mM Tris-HCl (pH 7.4 at room temperature) (buffer A) with a Polytron homogenizer (setting 7 for 10 s). The homogenates were centrifuged at 35000ϫg for 15 min at 4°C. The membrane pellets were resuspended in buffer A with a Teflon glass homogenizer (10 strokes by hand). Protein content was measured by the method of Lowry et al. 18 ]mesulergine. Nonspecific binding was defined with the use of 10 mM mianserin. For receptor binding using radioligand, incubations were carried out for 1 h at 37°C and were terminated by rapid filtration through Whatman GF/C filters that had been presoaked in 0.3% polyethyleneimine followed by washing with 10 ml ice-cold buffer A. The radioactivity retained on the filters was quantitated by liquid scintillation spectrophotometry.
Residue Numbering Scheme Receptor residues are numbered according to a consensus numbering scheme described previously. 20) On the basis of this scheme, the most conserved helix 3 residue, R152, is designated with the index number 3.50 and is thus referred to as R3.50. The '3' designates as helix 3 and '.50' the position of the most conserved locus in the helix. Residues C-terminal to this conserved locus are numbered in increasing order and N-terminal residues are numbered in decreasing order. Thus the Asp134 is referred to as Asp3.32. Similarly, the Ser361 in the helix 7 is referred to as Ser7.46.
Molecular Modeling
The approaches utilized to construct a three-dimensional model of the helix bundle of the 5-HT 2C receptor with sarpogrelate based on the structure of rhodopsin have been described previously.
13)
Data Analysis Nonlinear regression analysis of saturation and competition binding assay were performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, U.S.A.). The results of experiments are expressed as meanϮS.E.M. In competition binding experiments, the values of inhibition constants (Ki) were calculated by the following equation 21) and expressed as pKi (Ϫlog Ki).
where, the inhibition concentrations (IC 50 ) were determined as the concentrations of ligands that inhibited [ H]mesulergine for the receptors. In IP accumulation assay, the pKb values were estimated from the inhibitory effects of the antagonists on the concentration-dependent total inositol phosphate accumulation curve for serotonin according to the literature by Furchgott, 1972. 22) Tables 2 and 3 . RS 102221, a 5-HT 2C selective antagonist, exhibited high binding affinity (pKi value, 8.11Ϯ0.15) to the wild type receptor. Ketanserin (pKi value, 7.75Ϯ0.07) also showed high binding affinity, but its affinity is slightly lower than that of RS102221 although the values are not statistically significant. On the other hand, the pKi value (6.42Ϯ0.08) of sarpogrelate, a 5-HT 2A selective antagonist, was significantly lower than those of RS 102221 and ketanserin. Our data are consistent with the previous reports. 13, 23) In case of both the Asp3.32Ala mutant and the double mutant (Asp3.32Ala-Ser7.46Ala) receptors, it was not possible to find any sarpogrelate affinity to the mutants using the radioligand as the radioligand [ 3 H]mesulergine did not show any binding to the mutants. However, sarpogrelate showed a decreased binding affinity (pKi value, 4.87Ϯ0.17) to the Ser7.46Ala mutant receptors (Fig. 1B) .
Agonist-Stimulated Inositol Phosphate Accumulation The wild-type and mutant receptors were expressed in stably The best fit of the competition was monophasic and the Hill slope was near to Ϫ1. The data represent the meanϮS.E.M. of three to six separate experiments performed in duplicate. Tables 2 and 3 . The EC 50 value measured for 5-HT on the wild-type receptor was 67.8Ϯ4.0 nM. Inhibition of 5-HT-stimulated IP formation of the wild type receptor by several 5-HT 2 antagonists was shown in Fig. 2A . RS 102221 (5ϫ10 Ϫ7 M) shifted the concentration-response curve to the right without a change in the maximum response and its pKb value was 8.81Ϯ0.09. Ketanserin (10 Ϫ6 M) also showed high potency in inhibiting 5-HT-stimulated IP formation (pKb value, 7.81Ϯ0.08). On the other hand, the wild type receptor showed decreased sensitivity to sarpogrelate (2.5Ϯ10
with a pKb value of 5.96Ϯ0. 19 .
Mutation of the Asp3.32Ala and the double mutation (Asp3.32Ala-Ser7.46Ala) eliminated detectable IP accumulation. But introducing the mutation in helix 7 Ser7.46Ala reduced 5-HT-induced IP formation (25-fold) as indicated by an increased EC 50 value for 5-HT (1682Ϯ67 nM). In case of the Ser7.46Ala mutant receptor, sarpogrelate (10 Ϫ3 M) exhibited a great (91-fold) loss of potency compared with the wild-type receptor and its pKb value was 4.0Ϯ0.07 in inhibiting 5-HT-stimulated IP formation (Table 3) .
Ser7.46Ala mutant 5-HT 2C receptor demonstrated increase in basal IP production relative to the wild-type 5-HT 2C receptor (Fig. 3) . The Ser7.46Ala mutant demonstrated a 2.5-fold increase in basal activity compared with the wild-type receptor. On the addition of 10 mM 5-HT, both the wild-type and mutant receptors produced a further increase in IP production. In this case, the Ser7.46Ala mutant demonstrated a 4.75 fold increase in IP production compared with the wild-type receptor. The results of these studies indicate that mutation of amino acid no. 361 (7.46) from Ser to Ala produces a constitutively active 5-HT 2C receptor displaying greater basal activity than wild-type 5-HT 2C receptor.
DISCUSSION
In an attempt to elucidate the molecular basis of sarpogrelate binding to 5-HT 2C receptor, the present study was undertaken to determine the binding sites of sarpogrelate to 5-HT 2C receptor by mutating the amino acids in the third and seventh transmembrane helices of the receptor. Molecular modeling of sarpogrelate to 5-HT 2C receptor 13) predicted that Asp3.32 in the helix 3 and Ser7.46 in the helix 7 may be the important binding sites of sarpogrelate as the hydrogen atom of the trimethyl ammonium of sarpogrelate interacts with the acidic function oxygen of Asp3.32 and carboxylate group oxygen of sarpogrelate is H-bonded by Ser7.46 OH group (Fig. 4) . Since alanine substitutions introduce changes in both charge or H-bonding capabilities and in size, potentially leaving a cavity in comparison to other side chains, these two amino acids were substituted by alanine. Evaluation of the mutant receptor using both ligand binding and functional assays of coupling to signal transduction provides an insight into the basis of the various functional effects observed following introduction of a mutation. We, therefore, analyzed the mutant receptors by both ligand binding and signal transduction assays. The effects of the mutations studied on the affinity of sarpogrelate correlated fully with the expectations from the computational modeling of sarpogrelate with the 5-HT 2C receptor.
Sarpogrelate Affinity for the 5-HT 2C Receptor: Comparison with Other Antagonists From the binding data, it is evident that sarpogrelate showed moderate binding affinity to 5-HT 2C receptor compared with other antagonists used in the study. Inhibition of 5-HT-stimulated IP formation by the antagonists resulted in results qualitatively similar to the binding assay results. The difference in the affinity of sarpogrelate from those of ketanserin and RS 102221 may be due to the chemical structure of sarpogrelate and the amino acid interaction sites of the 5-HT 2C receptor. The chemical structure of sarpogrelate is totally different from those of ke- (Table 2 ). This may be due to change in the physicochemical properties of the side chain of the receptor, such as, charge, hydrogen bonding potential, hydrophobicity, volume, and shape. 25) It is also assumed that sarpogrelate might not bind to other binding sites of the receptor. One explanation for this effect seen with the mutation of the receptor is that the functional effects of a mutation may depend not only on the common role of the side chain but also on the local environment that is unique to the particular receptor studied.
26) The Asp3.32Ala mutant may affect sarpogrelate-receptor interactions indirectly by distortion of the neighboring amino acid residues, which are responsible for the interaction with sarpogrelate. Introduction of the second mutation at position 7.46 failed to restore the function disrupted by the first mutation (Table 3 [27] [28] [29] el1, el2, il3, TMD2, TMD3, TMD6 and TMD7 of the TSH receptor, 30) TMD2, TMD3 and TMD7 of the rhodopsin receptor. 31, 32) These results suggest that amino acid mutations in the appropriate region of almost any TMD or loop may produce a constitutively active receptor. This greatly increases the probability that a single amino acid mutation could give rise to a constitutively active receptor. Previous studies reported that mutation in the C-terminal region of il3 to convert amino acid 312 (6.34) from Ser to Lys and amino acid 368 (7.53) in TMD7 of the 5-HT 2C receptor from Tyr to Gly, Gln, Met, Thr, Ser, Cys, and His produce highly constitutively active receptors. 26, 33) Therefore, it is likely that mutation in TMD7 of the 5-HT 2C receptor by converting amino acid 361 (7.46) to alanine may generate a constitutively active receptor. It has been noted that enhanced signal transduction in the absence of agonist is correlated with receptor expression levels. 34) In this study, mutating Ser7.46 to Ala causes a dramatic increase in the expression of the mutant receptors and basal IP production as assessed by saturation binding and signal transduction assays. It is also reported that constitutively active mutant receptors remain in activated state and they show high agonist affinity and higher agonist stimulated 2nd messenger accumulation. 35) In the present study, the Ser7.46Ala mutant 5-HT 2C receptor exhibited a 4.75 fold increase in 5-HT-stimulated IP production compared with the wild-type receptor. These data indicate that the 5-HT 2C receptor could be rendered constitutively active. Further investigation is essential for this constitutively active mutant to determine whether the 5-HT 2 antagonists display inverse agonist activity by examining the ability of the antagonists to inhibit the basal activity of the Ser7.46Ala mutant, which may contribute to their unique therapeutic profile.
In conclusion, the present study shows that Asp3.32 in TMD 3 and Ser7.46 in TMD7 are the important binding sites of sarpogrelate to the 5-HT 2C receptor. Our investigations also indicate that the 5-HT 2C receptor can be rendered constitutively active by changing amino acid 7.46 from serine to alanine. .
